FindTrial
Sign In

PF-07220060

DRUG8 trials

Sponsors

Pfizer

Conditions

Adenocarcinoma of LungBreast CancerBreast NeoplasmsHealthy AdultsHealthy ParticipantLiposarcomaLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic ER+ HER2- Breast Cancer

Phase 1

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Active, not recruitingNCT06206837
PfizerBreast Cancer
Start: 2024-02-19End: 2026-09-07Updated: 2026-02-27
A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060
CompletedNCT06897683
PfizerHealthy Adults
Start: 2025-03-21End: 2025-06-12Updated: 2025-11-25
A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants
CompletedNCT07130097
PfizerHealthy Participant
Start: 2025-08-14End: 2025-11-18Updated: 2026-04-20
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
CompletedNCT07160738
PfizerHealthy Adults
Start: 2025-09-22End: 2025-12-22Updated: 2026-04-03

Phase 2

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Active, not recruitingNCT04557449
PfizerAdenocarcinoma of Lung, Breast Neoplasms, Liposarcoma +1
Start: 2020-09-23End: 2027-11-23Updated: 2025-10-01
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
RecruitingNCT04606446
PfizerLocally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Start: 2020-11-16End: 2029-08-10Target: 320Updated: 2026-04-16
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
CompletedNCT06465368
PfizerBreast Cancer
Start: 2024-07-11End: 2025-07-10Updated: 2025-10-01

Phase 3

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Active, not recruitingNCT06760637
PfizerBreast Cancer
Start: 2025-01-06End: 2037-12-29Updated: 2026-05-19

Related Papers

Abstract PS1-10-25: Pharmacodynamic effects of the first-in-class CDK4-selective inhibitor atirmociclib (PF-07220060) in combination with endocrine therapy in tumors of patients with HR+/HER2− metastatic breast cancer
Clinical Cancer Research2026-02-17
PS5-09-30: A phase 1/2 trial evaluating the safety, tolerability, and efficacy of the KAT6 inhibitor, PF-07248144, in combination with vepdegestrant in patients with ER+/HER2− locally advanced or metastatic breast cancer
Clinical Cancer Research2026-02-17
Abstract P4-04-28: PF-07248144, a first-in-class KAT6 inhibitor, in patients with HR+ HER2− metastatic breast cancer: Updated results from phase 1 dose expansion study
Clinical Cancer Research2025-06-131 citations
Abstract P5-08-28: Randomized phase 2 window of opportunity trial comparing the effect of preoperative atirmociclib (PF-07220060) plus letrozole versus letrozole alone on Ki-67 tumor expression in postmenopausal women with HR+/HER2+ breast cancer
Clinical Cancer Research2025-06-13
Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).
Journal of Clinical Oncology2025-05-282 citations
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
Future Oncology2024-07-2965 citations
Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
Nature Medicine2024-06-0142 citations
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.
Journal of Clinical Oncology2024-06-016 citations
First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.
Journal of Clinical Oncology2024-06-013 citations
TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
Journal of Clinical Oncology2024-06-01
264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
ESMO Open2024-05-013 citations
Abstract 3217: Discovery of novel inhibitors of the epigenetic regulator Kat6a histone acetyl transferase and characterization of their anti-tumor activity
Cancer Research2024-03-221 citations
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
Journal of Clinical Oncology2023-06-0117 citations
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
Journal of Clinical Oncology2023-06-019 citations
Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition.
2023-05-0127 citations